Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest From Alaric DeArment

Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout

Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.

Clinical Trials Inflammation

Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint

The company is on track for a mid-2023 FDA filing, while executives suggested that they would likely pursue partnership for commercialization of the drug in Europe.

Clinical Trials Neurology

Phase III Results Could Boost Pfizer Revenue Ahead Of Xtandi’s Exclusivity Loss

Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.

Clinical Trials Cancer

Pharming Leniolisib Launch Will Require Identifying Patients With Ultra Rare APDS

The company sees leniolisib as a way to expand its US and global commercial footprint before bringing in additional rare disease assets.

Business Strategies Blood & Coagulation Disorders

Bellicum Weighs Options After Hitting Brakes On CAR-T Program

An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.

Business Strategies ImmunoOncology

SVB Failure Could Exacerbate Tight Credit, Drive Biopharma Consolidation

An economist told Scrip that banks could become more cautious about handing out loans to biotech start-ups, driving more M&A in the sector.

Financing Business Strategies
See All
UsernamePublicRestriction

Register